Boston Scientific (BSX) Stock: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$46.01
1.50 (3.37%)
▲
5d:
+4.24%
30d:
+3.12%
90d:
+3.98%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 28, 2026
4d
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BSX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BSX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$70.42
Based on 4.1% avg growth
INTRINSIC VALUE TODAY
$43.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $46.01, which is considered extended relative to its 30-day fair value range of $42.74 to $44.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.6) compared to its historical average (17.1). Remarkably, the market is currently pricing in an annual earnings decline of 7.4% over the next few years. This pessimistic expectation contrasts with the company's recent 15.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a uptrend. The price is approaching resistance at $46.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: BSX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $58.00 (+26.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BSX is in a uptrend. The price is approaching resistance at $46.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: BSX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $58.00 (+26.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$42.74 -
$44.83
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
33.3%
Protect Your Profits
Holding BSX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 26.1% below Wall St target ($58.00)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$42.74 -
$44.83
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$41.97
Resistance Level
$46.05
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.62
Wall Street Target
$58.00
(+26.1%)
Revenue Growth (YoY)
7.5%
Earnings Growth (YoY)
15.1%
Profit Margin
17.5%
Valuation Discount vs History
-7.4% cheaper
PE vs Historical
13.6 vs 17.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.4%
(market-implied from PE analysis)
1-Year Target
$42.61
(-7%)
2-Year Target
$39.45
(-14%)
3-Year Target
$36.53
(-21%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$45.85
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 4.1%)
$75.62
(+64%)
Base:
(SPY PE: 13.6, Growth: 4.1%)
$51.88
(+13%)
Bear:
(PE: 11.6, Growth: 4.1%)
$44.09
(-4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.02 | Current EPS (TTM): $2.47
Bull Case
$66.94
(+46%)
Analyst growth 36.7%, PE expands to 19.8
Base Case
$60.85
(+32%)
Market implied 36.7%, PE stable at 18.0
Bear Case
$30.27
(-34%)
Severe decline -20.0%, PE contracts to 15.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.6 to 17.1
Stabilization Target:
$57.74
(+25.5%)
PE Expansion Potential:
+25.5%
Share & Embed Analysis
Last updated: October 23, 2026 2:37 AM ET
Data refreshes hourly during market hours. Next update: 3:37 AM
Data refreshes hourly during market hours. Next update: 3:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 45 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 50 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 51 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 32 SELL |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 44 HOLD |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
